We are live on ! Find out more
HS

HighVista Strategies Portfolio holdings

AUM $362M
1-Year Est. Return 230.96%
This Fund
S&P 500
This Quarter Est. Return
+12.21%
1 Year Est. Return
+230.96%
3 Year Est. Return
+518.4%
5 Year Est. Return
+644.94%
10 Year Est. Return
+2,223.31%
AUM
$290M
AUM Growth
+$16.2M
Cap. Flow
-$4.34M
Cap. Flow %
-1.5%
Top 10 Hldgs %
25.51%
Holding
174
New
37
Increased
46
Reduced
48
Closed
32

Top Buys

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$3.3M
2
GEV icon
GE Vernova
GEV
+$2.82M
3
PTGX icon
Protagonist Therapeutics
PTGX
+$2.76M
4
DYN icon
Dyne Therapeutics
DYN
+$2.61M
5
AMZN icon
Amazon
AMZN
+$2.59M

Top Sells

Rank Stock Value
1
INSM icon
Insmed
INSM
+$6M
2
ETRN
Equitrans Midstream Corporation Common Stock
ETRN
+$4.02M
3
CERE
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
+$3.97M
4
MRUS
Merus
MRUS
+$2.23M
5
META icon
Meta Platforms (Facebook)
META
+$2.06M

Sector Composition

Rank Sector Weight
1 Healthcare 46.45%
2 Technology 15.69%
3 Consumer Discretionary 9.1%
4 Industrials 4.98%
5 Financials 4.34%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MSFT icon
26
Microsoft
MSFT
$3.76T
$3.12M 1.08%
7,258
-1,900
-21% -$812K
SYRE icon
27
Spyre Therapeutics
SYRE
$9.29B
$3.1M 1.07%
105,351
-8,199
-7% -$228K
XOMA
28
DELISTED
Xoma
XOMA
$3.03M 1.05%
114,548
-4,351
-4% -$118K
KROS icon
29
Keros Therapeutics
KROS
$212M
$3.03M 1.04%
52,107
+12,899
+33% +$637K
NUVL
30
DELISTED
Nuvalent
NUVL
$2.97M 1.02%
29,018
+320
+1% +$26.5K
XENE icon
31
Xenon Pharmaceuticals
XENE
$6.21B
$2.9M 1%
73,762
+1,047
+1% +$42.2K
ELVN icon
32
Enliven Therapeutics
ELVN
$4.35B
$2.87M 0.99%
112,459
-7,330
-6% -$170K
OLMA icon
33
Olema Pharmaceuticals
OLMA
$1.04B
$2.53M 0.87%
212,185
-35,695
-14% -$456K
RVMD icon
34
Revolution Medicines
RVMD
$44.4B
$2.52M 0.87%
55,562
+15,479
+39% +$674K
COGT icon
35
Cogent Biosciences
COGT
$7.1B
$2.44M 0.84%
225,633
-55,460
-20% -$540K
EWTX icon
36
Edgewise Therapeutics
EWTX
$4.84B
$2.37M 0.82%
+88,838
New +$1.77M
DYN icon
37
Dyne Therapeutics
DYN
$4.95B
$2.35M 0.81%
+65,482
New +$2.61M
PFSI icon
38
PennyMac Financial
PFSI
$3.94B
$2.2M 0.76%
19,337
+6,100
+46% +$625K
MLTX icon
39
MoonLake Immunotherapeutics
MLTX
$1.47B
$2.2M 0.76%
43,541
+1,292
+3% +$60.5K
BABA icon
40
Alibaba
BABA
$317B
$2.16M 0.75%
20,357
+4,300
+27% +$352K
GOOG icon
41
Alphabet (Google) Class C
GOOG
$4.35T
$2.1M 0.72%
12,536
+1,100
+10% +$186K
ADSK icon
42
Autodesk
ADSK
$54.1B
$2.07M 0.71%
+7,500
New +$1.89M
TVTX icon
43
Travere Therapeutics
TVTX
$5.74B
$2.06M 0.71%
147,233
-72,183
-33% -$752K
PTC icon
44
PTC
PTC
$16.4B
$2.02M 0.7%
11,181
+600
+6% +$105K
LAUR icon
45
Laureate Education
LAUR
$5.13B
$2.02M 0.7%
121,607
+9,500
+8% +$145K
RYTM icon
46
Rhythm Pharmaceuticals
RYTM
$7.95B
$1.96M 0.68%
37,426
+23,064
+161% +$1.11M
AUTL
47
Autolus Therapeutics
AUTL
$551M
$1.93M 0.67%
533,024
+14,204
+3% +$56.6K
MRC
48
DELISTED
MRC Global
MRC
$1.91M 0.66%
149,800
+15,200
+11% +$197K
LAD icon
49
Lithia Motors
LAD
$8.35B
$1.91M 0.66%
+6,000
New +$1.67M
DAL icon
50
Delta Air Lines
DAL
$58.7B
$1.89M 0.65%
+37,200
New +$1.62M
1
2
3 4 5

Similar funds

SIAG
Safeguard Investment Advisory Group Corona, California $362M AUM 20.96% 1-Year Est. Return
MS
Millington Securities Red Bank, New Jersey $362M AUM
WI
WBI Investments Red Bank, New Jersey $362M AUM 23.75% 1-Year Est. Return
WTFG
Wood Tarver Financial Group Boise, Idaho $362M AUM 14.75% 1-Year Est. Return
VIA
Virtus Investment Advisers Hartford, Connecticut $363M AUM 34.89% 1-Year Est. Return
A6
Anchor @ 65 Singapore $362M AUM 20.02% 1-Year Est. Return
PI
Pennant Investors Summit, New Jersey $361M AUM 134.26% 1-Year Est. Return
ACM
Anfield Capital Management Irvine, California $363M AUM 24.08% 1-Year Est. Return

HighVista Strategies's Q3 2024 Portfolio in Review

As of Q3 2024, HighVista Strategies held 174 positions worth $290M, up 5.9% from $274M the previous quarter. Its ten largest holdings account for 26% of the portfolio.

HighVista Strategies's Q3 2024 filing shows 37 new, 46 increased, 48 reduced and 32 closed positions. Its largest new stake was Amgen: 10,101 shares worth $3.25M. The largest sale was Insmed, an estimated $6M.

By sector, the portfolio is most concentrated in Healthcare at 46% of assets, up from 44% a quarter earlier, followed by Technology and Consumer Discretionary.

  • HighVista Strategies's largest Q3 2024 buy was Amgen: 10,101 shares worth $3.25M.
  • HighVista Strategies added most to Protagonist Therapeutics in Q3 2024, an estimated $2.76M increase.
  • HighVista Strategies's biggest Q3 2024 reduction was Insmed, cutting an estimated $6M.
  • HighVista Strategies fully exited Equitrans Midstream Corporation Common Stock in Q3 2024, selling an estimated $4.02M.
  • HighVista Strategies's ten largest holdings make up 26% of its $290M portfolio in Q3 2024.
  • HighVista Strategies opened 37 new positions and closed 32 in Q3 2024.
  • HighVista Strategies's portfolio value rose 5.9% quarter-over-quarter to $290M.

Based on HighVista Strategies's 13F filing for Q3 2024, filed 14 Nov 2024.